VoxAmericana.com

A simple way to understand health care prices is to treat them like a receipt you never get to see.

Imagine you walk into a pharmacy to pick up insulin. You have insurance. You assume insurance means the price should be reasonable. Then the pharmacist tells you the cost, and it feels like you are buying a luxury item instead of a life sustaining medicine.

That sticker shock is not always because the insulin itself is getting more expensive to make. It is often because the insulin travels through a chain of middlemen, and each link in that chain can take a cut in a way that most patients never see.

That is what I mean by the Middleman Index. Pick one product. Follow it from the manufacturer to the patient. At each stop, ask two questions. Who gets paid? And is the payment tied to making the product cheaper, or to keeping the price high?

Step 1: The list price is the sticker price, not the real price

Insulin has a strange feature: the number you hear about in the news is often the list price, but the manufacturer may receive far less after discounts and rebates. According to a peer reviewed analysis of 32 insulin products, average list prices rose from 2014 to 2018 while average net prices received by manufacturers fell, meaning the gap between list and net got much larger over time.  

In normal shopping, the sticker price is close to what the seller gets. In insulin, the sticker price can be more like a starting point for negotiations behind the scenes.

Step 2: The hidden negotiation layer

Now enter the pharmacy benefit manager, often called a PBM. Most people never choose a PBM and never see one, but PBMs help decide which drugs your insurance will cover easily and which drugs come with hassles or higher costs.

Here is the everyday version of how the system can go wrong.

A PBM can tell a manufacturer, if you want your insulin to be the preferred option, you need to give us a rebate. A rebate is money that moves after the sale, kind of like a secret refund paid to the buyer side of the market.

The important part is the incentive. If the PBM is paid more when rebates are larger, then a higher list price can produce a bigger rebate and more profit, even if the true net price is lower. The Federal Trade Commission put this concern in blunt terms. According to the FTC, its 2024 complaint alleges that insulin products with higher list prices can generate higher rebates and fees for PBMs and affiliated purchasing groups, without additional services provided in exchange.  

That is a key Middleman Index insight: a system can reward the appearance of a discount while still pushing the sticker price up.

Step 3: Your insurance plan can make the sticker price matter to you

You might ask, if the manufacturer gives rebates and the plan gets discounts, why do I still pay so much at the counter.

One reason is benefit design. Many plans make you pay a share of the cost through deductibles or coinsurance. If that share is calculated using list price style numbers, then you can feel the pain of a high list price even when the net price in the background is lower.

This is why two people can have the same prescription and wildly different bills. One has a flat copay. The other has a deductible and coinsurance, and their share is tied to the higher sticker price.

Step 4: The pharmacy is the face of the system, not the engine

By the time you reach the pharmacy counter, the pharmacist is not setting the price. The pharmacy is following contracts and reimbursement rules set by the plan and PBM. This is one reason patients get frustrated. The only person they can talk to is the one who has the least control.

So what is the Middleman Index in plain English

It is a simple scorecard.

How far is the price you pay from the money that actually reaches the manufacturer. And how many players take money in between.

If the gap keeps growing, that is a signal that the system is paying more for complexity than for care.

What reforms the Middleman Index points toward

First, make the money trail visible. Patients should be able to see, in plain language, how much of the cost is list price, how much was negotiated away, and whether savings were applied to them at the counter.

Second, change incentives so middlemen are paid for lowering costs, not for extracting bigger rebates. The FTC lawsuit and broader scrutiny are rooted in this exact concern about rebate driven incentives.  

Third, protect patients directly where they feel it, at the pharmacy counter. According to KFF, the Inflation Reduction Act provides a $35 monthly insulin copay cap in Medicare Part D plans in 2024, which is an example of policy aimed at reducing point of sale burden.  

The bottom line is not complicated. If patients keep paying prices that feel unreal, it is usually because the pricing system is not built like a normal market. It is built like a maze. The Middleman Index is a way to map the maze, layer by layer, until the money story becomes as clear as the medical need.